Sharps Compliance Corp.
Sharps Compliance Corp. (SMED) Stock Competitors & Peer Comparison
See (SMED) competitors and their performances in Stock Market.
Peer Comparison Table: Waste Management Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SMED | $8.75 | +0.00% | 0 | 36.46 | $0.24 | N/A |
| WM | $227.26 | -1.45% | 92.4B | 34.57 | $6.64 | +1.37% |
| RSG | $241.46 | -1.49% | 76.6B | 37.02 | $6.62 | +0.95% |
| WCN | $186.10 | -1.14% | 48.3B | 75.40 | $2.48 | +0.66% |
| GFLU | $70.30 | +4.32% | 25B | -91.90 | -$0.77 | N/A |
| GFL | $47.81 | -0.46% | 17.1B | -31.31 | -$1.54 | +0.12% |
| CLH | $233.81 | +1.24% | 12.6B | 32.60 | $7.22 | N/A |
| CWST | $108.37 | -0.39% | 6.8B | 495.27 | $0.22 | N/A |
| SRCL | $61.98 | +0.83% | 5.8B | 158.92 | $0.39 | N/A |
| HCCI | $45.51 | +0.09% | 1.1B | 14.22 | $3.20 | N/A |
Stock Comparison
SMED vs WM Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, WM has a market cap of 92.4B. Regarding current trading prices, SMED is priced at $8.75, while WM trades at $227.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas WM's P/E ratio is 34.57. In terms of profitability, SMED's ROE is +0.34%, compared to WM's ROE of +0.33%. Regarding short-term risk, SMED is less volatile compared to WM. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check WM's competition here
SMED vs RSG Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, RSG has a market cap of 76.6B. Regarding current trading prices, SMED is priced at $8.75, while RSG trades at $241.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas RSG's P/E ratio is 37.02. In terms of profitability, SMED's ROE is +0.34%, compared to RSG's ROE of +0.18%. Regarding short-term risk, SMED is less volatile compared to RSG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check RSG's competition here
SMED vs WCN Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, WCN has a market cap of 48.3B. Regarding current trading prices, SMED is priced at $8.75, while WCN trades at $186.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas WCN's P/E ratio is 75.40. In terms of profitability, SMED's ROE is +0.34%, compared to WCN's ROE of +0.08%. Regarding short-term risk, SMED is less volatile compared to WCN. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check WCN's competition here
SMED vs GFLU Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, GFLU has a market cap of 25B. Regarding current trading prices, SMED is priced at $8.75, while GFLU trades at $70.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas GFLU's P/E ratio is -91.90. In terms of profitability, SMED's ROE is +0.34%, compared to GFLU's ROE of N/A. Regarding short-term risk, SMED is less volatile compared to GFLU. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GFLU's competition here
SMED vs GFL Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, GFL has a market cap of 17.1B. Regarding current trading prices, SMED is priced at $8.75, while GFL trades at $47.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas GFL's P/E ratio is -31.31. In terms of profitability, SMED's ROE is +0.34%, compared to GFL's ROE of +0.40%. Regarding short-term risk, SMED is less volatile compared to GFL. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GFL's competition here
SMED vs CLH Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CLH has a market cap of 12.6B. Regarding current trading prices, SMED is priced at $8.75, while CLH trades at $233.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CLH's P/E ratio is 32.60. In terms of profitability, SMED's ROE is +0.34%, compared to CLH's ROE of +0.15%. Regarding short-term risk, SMED is less volatile compared to CLH. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CLH's competition here
SMED vs CWST Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CWST has a market cap of 6.8B. Regarding current trading prices, SMED is priced at $8.75, while CWST trades at $108.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CWST's P/E ratio is 495.27. In terms of profitability, SMED's ROE is +0.34%, compared to CWST's ROE of +0.01%. Regarding short-term risk, SMED is less volatile compared to CWST. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CWST's competition here
SMED vs SRCL Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, SRCL has a market cap of 5.8B. Regarding current trading prices, SMED is priced at $8.75, while SRCL trades at $61.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas SRCL's P/E ratio is 158.92. In terms of profitability, SMED's ROE is +0.34%, compared to SRCL's ROE of +0.01%. Regarding short-term risk, SMED is more volatile compared to SRCL. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check SRCL's competition here
SMED vs HCCI Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, HCCI has a market cap of 1.1B. Regarding current trading prices, SMED is priced at $8.75, while HCCI trades at $45.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas HCCI's P/E ratio is 14.22. In terms of profitability, SMED's ROE is +0.34%, compared to HCCI's ROE of +0.22%. Regarding short-term risk, SMED is more volatile compared to HCCI. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check HCCI's competition here
SMED vs MEG Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, MEG has a market cap of 801.7M. Regarding current trading prices, SMED is priced at $8.75, while MEG trades at $23.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas MEG's P/E ratio is -10.06. In terms of profitability, SMED's ROE is +0.34%, compared to MEG's ROE of -0.15%. Regarding short-term risk, SMED is less volatile compared to MEG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check MEG's competition here
SMED vs NVRI Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, NVRI has a market cap of 754.3M. Regarding current trading prices, SMED is priced at $8.75, while NVRI trades at $9.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas NVRI's P/E ratio is -6.29. In terms of profitability, SMED's ROE is +0.34%, compared to NVRI's ROE of -0.28%. Regarding short-term risk, SMED is less volatile compared to NVRI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check NVRI's competition here
SMED vs HSC Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, HSC has a market cap of 729.6M. Regarding current trading prices, SMED is priced at $8.75, while HSC trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas HSC's P/E ratio is -5.08. In terms of profitability, SMED's ROE is +0.34%, compared to HSC's ROE of -0.32%. Regarding short-term risk, SMED is less volatile compared to HSC. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check HSC's competition here
SMED vs AMBI Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, AMBI has a market cap of 257.7M. Regarding current trading prices, SMED is priced at $8.75, while AMBI trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas AMBI's P/E ratio is -66.43. In terms of profitability, SMED's ROE is +0.34%, compared to AMBI's ROE of -0.00%. Regarding short-term risk, SMED is less volatile compared to AMBI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check AMBI's competition here
SMED vs PESI Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, PESI has a market cap of 227.4M. Regarding current trading prices, SMED is priced at $8.75, while PESI trades at $12.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas PESI's P/E ratio is -9.94. In terms of profitability, SMED's ROE is +0.34%, compared to PESI's ROE of -0.37%. Regarding short-term risk, SMED is less volatile compared to PESI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check PESI's competition here
SMED vs LNZA Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, LNZA has a market cap of 135.1M. Regarding current trading prices, SMED is priced at $8.75, while LNZA trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas LNZA's P/E ratio is -0.87. In terms of profitability, SMED's ROE is +0.34%, compared to LNZA's ROE of -2.96%. Regarding short-term risk, SMED is less volatile compared to LNZA. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check LNZA's competition here
SMED vs QRHC Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, QRHC has a market cap of 44.9M. Regarding current trading prices, SMED is priced at $8.75, while QRHC trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas QRHC's P/E ratio is -1.81. In terms of profitability, SMED's ROE is +0.34%, compared to QRHC's ROE of -0.44%. Regarding short-term risk, SMED is less volatile compared to QRHC. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check QRHC's competition here
SMED vs ENGS Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, ENGS has a market cap of 42.9M. Regarding current trading prices, SMED is priced at $8.75, while ENGS trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas ENGS's P/E ratio is -43.00. In terms of profitability, SMED's ROE is +0.34%, compared to ENGS's ROE of +0.28%. Regarding short-term risk, SMED is less volatile compared to ENGS. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check ENGS's competition here
SMED vs LICY Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, LICY has a market cap of 29.9M. Regarding current trading prices, SMED is priced at $8.75, while LICY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas LICY's P/E ratio is -0.15. In terms of profitability, SMED's ROE is +0.34%, compared to LICY's ROE of -0.34%. Regarding short-term risk, SMED is less volatile compared to LICY. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check LICY's competition here
SMED vs JAN Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, JAN has a market cap of 27.1M. Regarding current trading prices, SMED is priced at $8.75, while JAN trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas JAN's P/E ratio is -0.51. In terms of profitability, SMED's ROE is +0.34%, compared to JAN's ROE of +0.34%. Regarding short-term risk, SMED is less volatile compared to JAN. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check JAN's competition here
SMED vs CHRA Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CHRA has a market cap of 20.3M. Regarding current trading prices, SMED is priced at $8.75, while CHRA trades at $5.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CHRA's P/E ratio is -0.15. In terms of profitability, SMED's ROE is +0.34%, compared to CHRA's ROE of +20.59%. Regarding short-term risk, SMED is more volatile compared to CHRA. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check CHRA's competition here
SMED vs DXST Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, DXST has a market cap of 18.8M. Regarding current trading prices, SMED is priced at $8.75, while DXST trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas DXST's P/E ratio is 9.62. In terms of profitability, SMED's ROE is +0.34%, compared to DXST's ROE of +0.54%. Regarding short-term risk, SMED is less volatile compared to DXST. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check DXST's competition here
SMED vs GWAV Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, GWAV has a market cap of 16.6M. Regarding current trading prices, SMED is priced at $8.75, while GWAV trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas GWAV's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to GWAV's ROE of -0.64%. Regarding short-term risk, SMED is less volatile compared to GWAV. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GWAV's competition here
SMED vs CDTG Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CDTG has a market cap of 11.3M. Regarding current trading prices, SMED is priced at $8.75, while CDTG trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CDTG's P/E ratio is 6.57. In terms of profitability, SMED's ROE is +0.34%, compared to CDTG's ROE of +0.04%. Regarding short-term risk, SMED is less volatile compared to CDTG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CDTG's competition here
SMED vs AWX Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, AWX has a market cap of 10.3M. Regarding current trading prices, SMED is priced at $8.75, while AWX trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas AWX's P/E ratio is 12.62. In terms of profitability, SMED's ROE is +0.34%, compared to AWX's ROE of +0.02%. Regarding short-term risk, SMED is less volatile compared to AWX. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check AWX's competition here
SMED vs AQMS Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, AQMS has a market cap of 5.2M. Regarding current trading prices, SMED is priced at $8.75, while AQMS trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas AQMS's P/E ratio is -0.14. In terms of profitability, SMED's ROE is +0.34%, compared to AQMS's ROE of -1.51%. Regarding short-term risk, SMED is less volatile compared to AQMS. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check AQMS's competition here
SMED vs CHNR Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CHNR has a market cap of 4.6M. Regarding current trading prices, SMED is priced at $8.75, while CHNR trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CHNR's P/E ratio is -10.14. In terms of profitability, SMED's ROE is +0.34%, compared to CHNR's ROE of -0.00%. Regarding short-term risk, SMED is less volatile compared to CHNR. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CHNR's competition here
SMED vs ECOL Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, ECOL has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while ECOL trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas ECOL's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to ECOL's ROE of +0.01%. Regarding short-term risk, SMED is more volatile compared to ECOL. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check ECOL's competition here
SMED vs ECOLW Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, ECOLW has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while ECOLW trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas ECOLW's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to ECOLW's ROE of +0.01%. Regarding short-term risk, SMED is more volatile compared to ECOLW. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check ECOLW's competition here
SMED vs CVA Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, CVA has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while CVA trades at $20.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas CVA's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to CVA's ROE of -0.08%. Regarding short-term risk, SMED is less volatile compared to CVA. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CVA's competition here
SMED vs NES Comparison July 2025
SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMED stands at 0. In comparison, NES has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while NES trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMED currently has a P/E ratio of 36.46, whereas NES's P/E ratio is -1.32. In terms of profitability, SMED's ROE is +0.34%, compared to NES's ROE of -0.29%. Regarding short-term risk, SMED is less volatile compared to NES. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check NES's competition here